About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, September 24th, 2014

The QualityStocks
Daily Stock List

graphic
graphic

Nano Labs Corp. (CTLE)

Jet-Life Penny Stocks, Center Stage Stocks, PennyStocks24, Daily Stock Motion, RockingPennyStocks, OTPicks, PennyDoctor, Otcstockexchange, Penny Pick Insider, Penny Stocks VIP, Whisper from Wall Street, Wallstreet Profiler, and DSR News reported recently on Nano Labs Corp. (CTLE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Established in October 2012, Nano Labs Corp. is a nanotechnology research and development company that lists on the OTC Bulletin Board. The Company is able to access resources that include close to three decades of research and development in nanotechnology, and hundreds of peer-reviewed and published research papers and other scholarly material. Nano Labs is based in Detroit, Michigan. 

Nano Labs’ research and development team of scientists, designers, and engineers focuses on creating a portfolio of advanced products that could provide benefits to a variety of industries. These industries include consumer products, energy, materials, and healthcare.

The Company’s goal (via the use and integration of proprietary nano compounds) is to develop common products into new, innovative products to make the world a better place. The Company’s products and system solutions aspire to conserve resources, to enhance access to better health and nutrition, and to improve quality of life.

Nano Labs’ focus is in main areas relating to next-generation product solutions. These include Energy (including activities relating to generation, distribution, and storage); Materials (including the manufacture of building products, coatings, and paints), and Mining (including water and environmental technology and production process technology).

The Company has signed an agreement to produce Pol-Ec Tecnosoil. The Tecnosoil, when applied to sand, earth or clay, turns the surface to durable cement. Pol-Ec Tecnosoil can be used to build cement roads without the use of aggregates or concrete. Therefore, this process considerably reduces infrastructure costs.

Last week, Nano Labs announced that it finalized a Joint Venture (JV) Agreement with DB Metals SA to conduct a business development Program (BDP) for the benefit of the parties exploiting and scaling up DB Metals’ novel technology. The JV Agreement outlines to transform DB Metals in a JV company for operational and funding Therefore, Nano Labs will be able to address market opportunities. DB Metals will be responsible for adapting and addressing market opportunities globally.

DB Metals is a technology based company located in Mexico. It has been developing a novel technology consisting of a three phase metallurgical process, which enables the substantial reduction of time and raw materials needed to recycle lead and other non-ferrous metals. 

Nano Labs Corp. (CTLE), closed Wednesday's trading session at $0.0178, down 3.26%, on 1,329,389 volume with 28 trades. The average volume for the last 60 days is 1,147,256 and the stock's 52-week low/high is $0.0101/$0.13.

Nuvilex, Inc. (NVLX)

OTCJournal, PennyStocks24, Penny Stock Rumble, The Green Baron, Stock Market Media Group, SmallCapVoice, First Penny Picks, StocksImpossible, Trading Wall St, and DSR News reported earlier on Nuvilex, Inc. (NVLX), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Nuvilex, Inc. is a clinical-stage, global biotechnology company headquartered in Silver Spring, Maryland.  It provides cell and gene therapy solutions for the treatment of deadly diseases. The Company is focusing on developing and preparing to commercialize treatments for cancer, diabetes, and other diseases founded on the live, therapeutically valuable, encapsulated cells platform. Nuvilex is leveraging its cancer biology and clinical oncology research experience and expertise, especially for use in oncology treatments, in addition to initiating oncology applications of medical marijuana.

Nuvilex is concentrating on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology called Cell-in-a-Box®. This unique technology will be used as a platform upon which treatments for several types of cancer (including advanced, inoperable pancreatic cancer) and diabetes are being built. Nuvilex's treatment for pancreatic cancer involves the use of the extensively used anticancer prodrug ifosfamide in tandem with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form.

Nuvilex's subsidiary is Medical Marijuana Sciences, Inc. Medical Marijuana Sciences’ commitment is to the development of cancer treatments based upon chemical constituents of marijuana - called cannabinoids. To do so, Nuvilex will examine ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids against cancers. This is while minimizing or outright eliminating the debilitating side effects typically associated with cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop "green" approaches to fighting deadly cancers.

Nuvilex has completed the required preliminary steps to start a Phase 2b clinical trial of its pancreatic cancer treatment that it expects to begin in Q1 2015. Its treatment (Cell-in-a-Box®plus ifosfamide) will be compared one-on-one with the best available therapy (presently Abraxane® plus gemcitabine) for advanced, inoperable pancreatic cancer.

In August, Nuvilex announced that its partner, Austrianova, reported that results from the second Phase 2 clinical trial (combining the Cell-in-a-Box® cellulose-based live cell encapsulation technology plus low doses of the anticancer prodrug ifosfamide in patients with advanced, inoperable cancer) has been published in the scientific journal Pharmaceutics. The title of the publication is "Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious: Data from Two Clinical Trials in Pancreatic Cancer." 

Last week, Nuvilex provided its shareholders with an update on recent activities of Nuvilex and outlined future plans for the development of treatments in the areas of cancer and diabetes. 

Nuvilex CEO/President, Kenneth L. Waggoner, stated "The progress that Nuvilex has made in the past nine months and we expect to continue to make during the balance of this year is truly impressive. Not only is the development of our pancreatic cancer treatment moving forward on all fronts, but the development of a treatment for type 1 diabetes has finally been launched."

Nuvilex, Inc. (NVLX), closed Wednesday's trading session at $0.175, down 2.13%, on 1,775,428 volume with 212 trades. The average volume for the last 60 days is 2,018,065 and the stock's 52-week low/high is $0.0201/$0.62.

RealBiz Media Group, Inc. (RBIZ)

SmallCapVoice reported recently on RealBiz Media Group, Inc. (RBIZ), Pumps and Dumps, Ascending Stocks, and HotStockProfits did earlier, and we highlight the Company today, here at the QualityStocks Daily Newsletter.

RealBiz Media Group, Inc. is a real estate digital media and technology company that lists on the OTCQB. The Company’s proprietary video processing technology makes it one of the leaders in providing home video tours to the real estate industry. Its client base includes more than 350,000 real estate agents and brokers. The Company was previously known as Webdigs, Inc. It changed its name to RealBiz Media Group, Inc. in October 2012. Founded in 2007, RealBiz Media Group has its corporate office in Fallbrook, California. EzFlix, LLC is a wholly owned subsidiary of RealBiz Media Group.

The Company provides a series of products including a consumer portal www.nestbuilder.com, an agent-only platform called Nestbuilder Agent, a television video on demand network, a growing MVA network, Virtual Tours, and Mobile Apps. RealBiz Media Group has access to the country’s largest real estate companies with many approved vendors and national contracts.

RealBiz Media Group announced this past May the acquisition of ReachFactor, Inc.  ReachFactor is a social media marketing platform. It helps real estate agents and brokerages grow their online visibility, connect with customer prospects, as well as turn those prospects into new customers.

This acquisition adds depth to RealBiz Media Group's agent products, brings thousands of agent subscribers, and expands the Company’s ability to market its services directly to highly engaged real estate agents. ReachFactor has become a trusted resource by more than 250,000 real estate agents. These agents have subscribed to ReachFactor’s free newsletter filled with marketing tips and online lead generation tactics for the real estate industry.

In August, RealBiz Media Group announced that it entered into contracts to provide its video marketing services to two national real estate franchises controlled by Realogy Holdings Corp. Full terms of the agreements were not released. Nevertheless, the combined contracts cover a two-year term with associated revenues greater than $1 million dollars. Realogy Holdings is a worldwide leader in residential real estate franchising with around 13,500 offices with 251,000 independent sales associates doing business in 104 countries worldwide.

This month, RealBiz Media Group’s EzFlix subsidiary announced that its ezflix™ mobile app for real estate agents will be available from the Google Play® store this month. ezflix will be the only mobile app available to real estate agents that pre-integrates property listings from multiple listings services (MLS) so that agents can subsequently create and customize digital material including video, mini commercials, neighborhood tours, and community events to provide prospective buyers more context about every listing.

RealBiz Media Group, Inc. (RBIZ), closed Wednesday's trading session at $0.1649, up 3.06%, on 12,100 volume with 2 trades. The average volume for the last 60 days is 52,008 and the stock's 52-week low/high is $0.0701/$4.65.

Green Automotive Co. (GACR)

TheBombPennyStocks, PennyStock24, Featured PS Report, Growing Stocks Reports, Michael Stone, Research Driven Alerts, PennyStocks Forever, Research Driven Investor, and The Street reported earlier on Green Automotive Co. (GACR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Green Automotive Co. is a state-of-the-art niche vehicle design, engineering, manufacturing, and sales company. Green Automotive, through its subsidiaries, focuses on the design, engineering, manufacture, and sale of electric vehicles using zero and low emission technologies. In addition, it provides a complete after sales program maximizing the life time value of clean transport solutions.  Green Automotive has acquired California and Mexico-based Blackhawk Manufacturing, Inc. and its affiliated companies. Blackhawk is one of the top manufacturers of specialist composite materials with facilities in Bloomington, California and Tijuana, Mexico.

Green Automotive engages in vehicle technology development, engineering, and design with a focus on zero and low emission solutions; manufacturing and customization of vehicles for niche markets; and the above-mentioned after sales support programs for electric or low emission vehicles, including parts, servicing, and repair. Its three main subsidiaries are Liberty Electric Cars Ltd., Newport Coachworks, Inc., and GoinGreen Ltd.  Liberty Electric Cars designs and develops EV technologies for use in its converted vehicles and for sale to original equipment manufacturers (OEMs) for integration into production. It also provides a full aftermarket program for electric vehicle users.

Newport Coachworks specializes in building high quality shuttle buses, running on an array of energy sources from petrol and diesel through to compressed natural gas (CNG). GoinGreen pioneered electric vehicles in the UK with the G-Wiz. In 2012, GoinGreen embarked on a program to become the first one-stop shop for sales of all sustainable transport solutions. This is from electric bikes and scooters to electric motor bikes; from electric city cars to electric vans and trucks. 

Green Automotive has its first all American built, 100 percent pure electric shuttle bus - “The e-PATRIOT”.  The e-PATRIOT is manufactured at subsidiary Newport Coachworks’ facility in Riverside, California. This is where it has been manufacturing its complete range of shuttle buses since February of 2013. The e-PATRIOT can travel up to 100 miles on a single charge. It has a top speed of 60 mph and can be equipped with a fast charging system.

In early September, Green Automotive announced that it will sell the assets of its GoinGreen and LEC2 businesses to former GoinGreen staff members, led by Clive Southwell, former director of the UK business. Simultaneously, it will transfer the majority of the knowledge in its electric vehicle technology centre, called Liberty E-Tech, to a new facility to be opened in Riverside, California. Therefore, Green Automotive will end its electric vehicle retailing, engineering, and development and support operations in the UK. Green Automotive’s objective is to make Newport Coachworks the focus of the Company’s efforts to create a successful and sustainable business.

Green Automotive Co. (GACR), closed Wednesday's trading session at $0.0075, down 10.71%, on 1,106,350 volume with 33 trades. The average volume for the last 60 days is 1,788,927 and the stock's 52-week low/high is $0.005/$0.45.

Aja Cannafacturing, Inc. (AJAC)

We are highlighting Aja Cannafacturing, Inc. (AJAC) today, here at the QualityStocks Daily Newsletter.

Aja Cannafacturing, Inc. is a diversified holding company that lists on the OTC Bulletin Board. The Company has internal operations centered on creating superior long-term returns for shareholders by way of a unique structure of diversified public and non-public holdings. Its operations focus on being the ground-breaking force in the cannabis industry via the select breeding and cultivation of application-specific, proprietary cannabis seed. Scheduled products include a featured line known as "Cannaceuticals," a line of Cannabinoids produced to be base components for third party branding. Aja Cannafacturing has its corporate headquarters in Lake Elsinore, California.

The Company is furthering its mission of becoming a leading supplier of raw cannabis material for industry specific applications. This includes building materials (Hemp Crete), automotive (biofuels), plastics (healthcare) and textiles (fabrics), among others.

Aja Cannafacturing has two operating subsidiaries. One is Propel Management Group (PMG). PMG provides a complete spectrum of program management, acquisition, as well as lifecycle support services to its customers. The second operating subsidiary is Charge! Energy Storage, Inc. This subsidiary is a designer and developer of energy storage devices for residential, commercial, and light industrial markets.

Earlier this month, Aja Cannafacturing announced it appointed its first new member to its Board of Directors since changing its company name and trading symbol and subsequent transition to a new business model. Mr. Kendall A. Smith joined the Aja Cannafacturing Board effective September 22, 2014. Mr. Smith is currently the founder and co-owner of Smith & Ramsay, LLC. Smith & Ramsay is a Nevada-based company, whose specialty is flavoring and aroma extraction services in the food, beverage and vaporizer and e-Cigarette/eVapor industries.

Last week, Aja Cannafacturing announced its Board approved the divestiture of Charge! Energy Storage, through a dividend on a one-to-one basis upon regulatory approval. Aja stated this divestiture would permit the management of each Company to focus on its respective business model's growth and success.

Aja Cannafacturing, Inc. (AJAC), closed Wednesday's trading session at $0.006, up 140.00%, on 34,917,734 volume with 309 trades. The average volume for the last 60 days is 1,461,590 and the stock's 52-week low/high is $0.002/$0.0979.

Applied DNA Sciences, Inc. (APDN)

SuperNova Elite, Top Stock Tips, and Investor Ideas reported earlier on Applied DNA Sciences, Inc. (APDN), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Based in Stony Brook, New York, Applied DNA Sciences, Inc. is a provider of botanical-DNA based anti-counterfeiting technology and product authentication solutions. These solutions can help protect products, brands, and the intellectual property (IP) of companies, governments, and consumers from theft, counterfeiting, fraud and diversion. Its SigNature® DNA describes the uncopyable marker that is at the center of all of its security and authentication solutions. Applied DNA Sciences lists on the OTC Markets’ OTCQB.

SigNature® DNA is at the heart of its family of products. The foundation of SigNature® DNA is on full, double-stranded plant DNA. Applied DNA Sciences does not use single-stranded, “synthetic” DNA. The mark will not wash off, even in aggressive industrial treatment baths. Furthermore, results are not hidden or obscured by false positives. SigNature® DNA markers can be used to strengthen brand protection efforts; mark, track and convict criminals; and strengthen supply chain security.    

The Company’s products include digitalDNA®. This is a security tool, which uses the flexibility of mobile communications, the instant accessibility of secure, cloud-based data, and the absolute certainty of DNA to make item tracking and authentication quick, easy, and definitive. Moreover, products include DNAnet® forensic tagging systems. DNAnet intruder tagging systems help to expand and strengthen any security effort through providing a way of directly linking criminals to crimes.

Another product the Company offers is fiberTyping® textile genotyping. FiberTyping® is a DNA test developed in collaboration with Supima (representing U.S. pima cotton growers) to provide a way to verify original ELS cotton content present in cotton products. This past March, Applied DNA Sciences announced that the US Patent and Trademark Office (USPTO) issued patent no. 8,669,079 for Applied DNA Sciences’ fiberTyping® authentication of cotton-based products.

Last week, Applied DNA Sciences announced that its DNA authentication technology was recently used to interdict a shipment of mislabelled textiles resulting in more than $1 million of inventory held in quarantine. The products consist of a variety of yarn, finished fabric and garments, which could have been mislabelled, and then marketed and sold in retail outlets in the U.S. and internationally.

Applied DNA Sciences, Inc. (APDN), closed Wednesday's trading session at $0.092, down 5.54%, on 782,850 volume with 56 trades. The average volume for the last 60 days is 883,636 and the stock's 52-week low/high is $0.084/$0.189.

Marina Biotech, Inc. (MRNA)

SmarTrend Newsletters and SmallCapVoice reported previously on Marina Biotech, Inc. (MRNA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Marina Biotech, Inc. is a foremost nucleic acid-based drug discovery and development company focused on rare diseases. In essence, it is an oligonucleotide therapeutics enterprise with extensive drug discovery technologies providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics. These include siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messengerRNA therapeutics. OTCQB listed Marina Biotech is based in Bothell, Washington.

Its technologies were built through a roll-up strategy to discover and develop different types of nucleic acid therapeutics to modulate (up or down) a specific protein(s), which is either being produced too much or too little therefore causing a particular disease. The Company believes its technologies have unique strengths as a drug discovery engine for the development of nucleic acid-based therapeutics for rare and orphan diseases.

In addition, Marina Biotech believes it is the only company in the sector that has a delivery technology in human clinical trials with differentiated classes of payloads, via licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively.

Marina Biotech’s novel chemistries and other delivery technologies have been validated through license agreements with Roche, Novartis, Monsanto, and Tekmira. The Company is advancing CEQ508, for which it has received Food and Drug Administration (FDA) orphan drug designation, in a Phase 1 clinical program for patients with Familial Adenomatous Polyposis. It is expanding its rare disease focus to include myotonic dystrophy and Duchenne’s muscular dystrophy.

This month, Marina Biotech announced that it received patent protection for its comprehensive and diverse nucleic acid delivery platform with patent grants covering delivery technologies: SMARTICLES® in Europe; TransKingdom RNA™ interference (tkRNAi) in Japan; Di-terminal Amino Acid Lipids (DILA2) in Australia; and lipopeptide nucleic acid delivery in China. Marina Biotech has more than 100 issued or allowed patents and more than 90 pending U.S. and foreign patent applications.

Marina Biotech, Inc. (MRNA), closed Wednesday's trading session at $1.00, even for the day, on 94,755 volume with 35 trades. The average volume for the last 60 days is 122,570 and the stock's 52-week low/high is $0.195/$1.81.

graphic

The QualityStocks
Company Corner

graphic
graphic

One World Holdings, Inc. (OWOO)

The QualityStocks Daily Newsletter would like to spotlight One World Holdings, Inc. (OWOO). Today, One World Holdings, Inc. closed trading at $0.021, up 38.16%, on 90,001 volume with 5 trades. The stock’s average daily volume over the past 60 days is 206,337, and its 52-week low/high is $0.0101/$3.6154.

One World Holdings, Inc. subsidiary, The One World Doll Project, announced today that it has recently entered into an $800,000 private equity partnership with Blackbridge Capital, a New York hedge fund, and a group of private equity investors that will focus on debt reduction and balance sheet enhancement.

One World Holdings, Inc. (OWOO) subsidiary, The One World Doll Project, was established in 2010 to make a significant positive cultural impact through the doll category, transcending global and ethnic borders to create positive self-image in young women and girl around the world. Led by worldwide famous doll designer Stacy McBride-Irby, The One World Doll Project team has more than 50 collective years in the doll and toy industry and is dedicated and armed with the experience to ensure that the dolls are of the highest quality and value.

In 2013, the company released its Prettie Girls!™ line of multi-cultural fashion dolls uniquely designed with individual physical attributes, personal stories and hobbies, and goals and inspirations. For young girls, the dolls are a friend, a partner in play, and a glimpse of their biggest, brightest dreams. For young women, the dolls are a symbol of who they are and what they can achieve. For doll connoisseurs, The One World Doll Project promises stylish works of art that will become a vital part of a growing collectors’ market.

The One World Doll Project also has a Signature Celebrity Collection of Prettie Girls! and in 2013 released its first celebrity collectors doll modeled after supermodel Cynthia Bailey from The Real Housewives of Atlanta. Since the release of the doll, it has been showcased with Synthia on The Arsenio Hall Show, What Happens Live with Andy Cohen and The Bethenny Show.

Using a web-based sales model, One World Holdings plans to quickly capture significant market share in the dolls and stuffed toys space. After securing a strong online presence, the company will focus on brick and mortar retailing as it moves toward the ultimate pursuit of expanding worldwide. The company has established distribution deals with Toys “R” Us, HEB, dollgenie.com, Tuckers Toy Shop, pattycakedoll.com, and has recently expanded its retail presence internationally with the People’s Pharmacy storechain in the Central American country of Belize. The Prettie Girls! Dolls have been featured in national and international media spotlights like CNN, The Wall Street Journal, Jet Magazine, Bloomberg.com, Parade.com, Dolls Magazine, The Toy Book, The Houston Chronicle and Houston Business Journal, and TheStreet.com. Disclaimer

One World Holdings, Inc. Company Blog

One World Holdings, Inc. News:

The One World Doll Project Announces Financing Relationship With New York Hedge Fund, Blackbridge Capital

One World Holdings, Inc. Announces Engagement of QualityStocks Investor Relations Services

The One World Doll Project Announces New Online Distribution With Toys"R"UsŪ

Sibling Group Holdings, Inc. (SIBE)

The QualityStocks Daily Newsletter would like to spotlight Sibling Group Holdings, Inc. (SIBE). Today, Sibling Group Holdings, Inc. closed trading at $0.18, up 20.00%, on 100 volume with 1 trade. The stock’s average daily volume over the past 60 days is 50,017, and its 52-week low/high is $0.031/$0.24.

Sibling Group Holdings, Inc. announced today that it is offering its Special Education Courses on the Blended Schools Network ("BSN") division's teacher professional development platform. Educators are responsible for the learning of all students in their classrooms, but many are desperate for the resources and skills they need to be effective with special education students.

Sibling Group Holdings, Inc. (SIBE) is enhancing and delivering 21st century learning with advanced technology and education management operations. Accessing funds from the public capital markets is part of the company’s unified strategy to accelerate the improvement of Pre-K, K-12 and post-secondary education around the world. Better educated children and adults, sustainable and cost effective instructional models, and reduced dependence on governmental funding are the end results.

Existing offerings include professional development for the teaching profession; educational technology, including classroom management tools; a comprehensive and flexible online curriculum; an aggregation platform for massive open online courses, and academic and skills credentialing. Investments are being made in specialized curriculum such as STEM (science, technology, engineering and math), ESL (english as a second language), SEL (social and emotional learning), and Special Ed aimed at supporting students with special needs and their teachers.

Sibling Group is acquiring various Ed-tech businesses and components with the goal of building the first complete solution for the delivery and management of educational content, and tracking educational results, in the digital media – from curriculum to course certification. The recent acquisition of Blended Schools Network (BSN), which serves over 160 school districts with 300,000 course enrollments and currently offers 212 different online courses, is a great example and has provided Sibling Group with extensive infrastructure and solid groundwork for growth in a rapidly growing industry.

IBIS Capital is forecasting fifteen-fold growth in the e-learning market over the next 10 years and has even suggested that under certain circumstances the transition to digital education may be quicker and more disruptive than ever observed in the media industry. With a strong, highly experienced management team, Sibling Group is in a unique position to continue expanding its portfolio through additional acquisitions and fundamental growth. Disclaimer

Sibling Group Holdings, Inc. Company Blog

Sibling Group Holdings, Inc. News:

Sibling's Blended Schools Network Division Offers Special Education Professional Development for All Educators

Sibling's BSN Division Launches Teacher Professional Development on Udemy Global Marketplace

Sibling Group Holdings to Present at the National Investment Banking Association Investment Conference

Technology Applications International, Inc. (NUUU)

The QualityStocks Daily Newsletter would like to spotlight Technology Applications International, Inc. (NUUU). Today, Technology Applications International, Inc. closed trading at $1.48, even for the day. The stock’s average daily volume over the past 60 days is 2,417, and its 52-week low/high is $1.15/$4.50.

Technology Applications International, Inc. announced today that it has relocated its corporate headquarters and hub of operations to the Chase Bank Building, 150 SE 2nd Avenue, Miami, Florida, to be more conveniently located to the University of Miami Science Life and Technology Park. The Company also announced today, that it has chosen Adcom Worldwide Shipping and Distribution, a prestigious worldwide shipping company, to warehouse and ship its products globally.

Technology Applications International, Inc. (NUUU) is focused on producing, distributing, marketing and selling skincare products, in addition to engaging in the environmental management and water purification industries. The company conducts its business through two separate wholly owned subsidiaries: Rejuvel Int'l, Inc. and NueEarth, Inc.

Rejuvel Int'l, Inc. developed its skincare line of products using a NASA bioreactor to grow and expand three-dimensional fibroblast cells. Using exclusively licensed technology, licensed from the National Aeronautics and Space Administration and Administrators of the Tulane Educational Fund under U.S. Patent No. 6,730,498, the Rejuvel’s flagship anti-aging facial products trigger the multiplication of human fibroblast skin cells that rebuild skin for a firm, healthy and youthful appearance. The company has been awarded a “seal of approval” from the Space Certification program, setting a new standard for innovation in an industry projected to reach $114 billion in sales by 2015.

NueEarth, Inc. provides environmental management solutions and water purification techniques using a mobile electron beam accelerator unit which creates high-energy electrons that produce free radicals in the wastewater to decompose organic compounds or pollutants. The company has identified a number of different markets for this particle accelerator technology, including the removal of pollutants from wastewater, drinking water, municipal sludge and water that’s contaminated by the fracking process.

Technology Applications International’s management team is methodically establishing its brand in the marketplace with well-respected associations and strategic marketing initiatives. As the company continues to pursue direct consumer sales and other opportunities, it stands to do well with the foundation management has laid for growth. Disclaimer

Technology Applications International, Inc. Company Blog

Technology Applications International, Inc. News:

NUUU and its Wholly Owned Subsidiaries Rejuvel Int'l, Inc. and NueEarth, Inc. Has Announced That it Has Relocated its Headquarters

NUUU's Wholly Owned Subsidiary Rejuvel Int'l, Inc. Announces Production of Thirty Second Television Commercial

Technology Applications International Corporation Announces Name Change of Wholly Owned Subsidiary

Oriens Travel and Hotel Management Corp. (OTHM)

The QualityStocks Daily Newsletter would like to spotlight Oriens Travel and Hotel Management Corp. (OTHM). Today, Oriens Travel and Hotel Management Corp. closed trading at $0.0003, up 200.00%, on 25,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 24,497,996, and its 52-week low/high is $0.0001/$0.0024.

Oriens Travel and Hotel Management Corp. announced today that the Company has named Mr. Melvin Pereira as its new Chief Executive Officer, President & Director. As a result of the Company accepting a "Plan of Merger" during a special meeting of the Board of Directors, on Wednesday, September 10th, 2014; the nomination of Melvin Pereira was also made.

Oriens Travel and Hotel Management Corp. (OTHM) is a provider of proprietary technology, marketing solutions, infrastructure and branding services to hotel operators.

The company's innovative platform functions as a powerful vehicle to help hotel operators achieve greater success in three specific areas: (i) expanded international exposure and recognition, (ii) powerful core structure, and (iii) high occupancy rates that drive increases in bottom-line profits. Oriens continuously refines its suite of proprietary solutions to deliver measurable and proven results to hotel properties. This success has been reflected in those properties operating under the Hotel PURE brand as well as with independent boutique hotel properties utilizing the company's Friendly Reservation Online (FROL) booking engine technology and internet marketing services.

Operating a successful bi-lateral business model, Oriens has four objectives:

1. To franchise the Hotel PURE brand to selected hotel properties worldwide similar to the business model currently employed by Big Brand operators such as Holiday Inn, Marriott, Sheraton and others;

2. Provide highly efficient and economical back-end booking engine technology services to independently branded boutique hotels that require a robust online presence;

3. Launch a stand-alone online hotel booking search engine primarily focused on Central America; and,

4. Expand the portfolio of Oriens-owned boutique hotels operating under the Hotel PURE brand.

The company initially began growing its operations primarily in the United States. However most recently, major opportunities in Central America began presenting themselves, giving Oriens the ability to retool its business model. Now the company is positioned to acquire, own and operate its own properties – which would be marketed under the new brand with occupancies handled by the re-launched online booking engine system.

Ultimately, Oriens intends to become a top-tier hotel brand operator and Internet booking and marketing service provider, qualifying as a preferred supplier to lending institutions. The company also intends to establish an invaluable international footprint with its online booking engine technology and marketing offerings; making that segment of its business a prime acquisition target for major online travel search and booking engine companies. Advancement toward this goal is guided by an executive management team with deep expertise in technology, banking, management, hospitality, branding and marketing, technical development and more. Disclaimer

Oriens Travel and Hotel Management Corp. Company Blog

Oriens Travel and Hotel Management Corp. News:

International Hospitality Company Oriens Announces New CEO

Oriens' Merger Set to Close

Oriens' Board Accepts Plan of Merger

Zenosense, Inc. (ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.39, up 8.33%, on 411,149 volume with 131 trades. The stock’s average daily volume over the past 60 days is 47,304, and its 52-week low/high is $0.15/$1.00.

Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.

Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.

The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer

Zenosense, Inc. Company Blog

Zenosense, Inc. News:

Zenosense, Inc. Update -- MRSA and Lung Cancer Device Development

Zenosense, Inc. Begins Development of Lung Cancer Detection Device

Zenosense, Inc. Highlights Recent Media Coverage of MRSA

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $10.00, up 25.00%, on 100 volume with 1 trade. The stock’s average daily volume over the past 60 days is 50, and its 52-week low/high is $5.00/$17.80.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Receives Notice of Allowance for Canadian Patent, Further Expanding Stem Cell Technology Platform

VistaGen Announces Reverse Stock Split

VistaGen Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform

Falcon Crest Energy (FCEN)

The QualityStocks Daily Newsletter would like to spotlight Falcon Crest Energy (FCEN). Today, Falcon Crest Energy closed trading at $0.0361, up 0.28%, on 10,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 19,035, and its 52-week low/high is $0.0005/$0.095.

Falcon Crest Energy (FCEN) is a development stage oil and gas exploration and production company focused on developing properties in North America. The company plans to minimize the risk of exploration through development of proved petroleum reserves, and expects to maximize profit through strategic acquisition and liquidation of selected oil and gas properties.

The company specializes in acquiring low risk, high upside properties with substantial exploration potential. Through improvements in oil and gas production technologies, Falcon Crest Energy aims to rapidly increase production levels and generate predictable, sustainable value. The business strategy utilized calls for both 100% acquisitions and joint-ventures to maximize production capacity.

Evergreen Petroleum, a joint venture partner, is working closely with the company to explore oil-bearing formations in Wyoming. Evergreen has conducted and will continue to conduct both regional and local geological studies to define prospects that are worthy of acquiring oil and gas leases. By partnering with industry experts such as Evergreen, Falcon Crest Energy has strategically added extensive technical guidance and field management experience.

Even during challenging times, the world depends on oil & gas exploration and production companies to deliver millions of barrels of oil every day. Increased demand from emerging countries such as China further escalates competition for this precious resource. Backed by an experienced group of professionals, Falcon Crest Energy is well positioned to generate substantial revenues in the short and long term future. Disclaimer

Falcon Crest Energy Company Blog

Falcon Crest Energy News:

Falcon Crest Names Michael Cvetanovic to Advisory Council

Falcon Crest Energy Announces Powder River Basin Leasehold Acquisition

Panther Energy Changes Name to Falcon Crest Energy

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Real Pennies
(NXPS)

2.

QualityStocks
(OTHM)

3.

OTPicks
(THNS)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251